In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis.
about
Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease modelsFormation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectinAmyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytesSynthetic amyloid-beta oligomers impair long-term memory independently of cellular prion proteinDysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic miceTargeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsChronochemistry in neurodegenerationInteraction between prion protein and Aβ amyloid fibrils revisitedIntracellular cleavage of amyloid β by a viral protease NIa prevents amyloid β-mediated cytotoxicityAPOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectiveSynaptic transmission block by presynaptic injection of oligomeric amyloid betaDisruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid betaLipid microdomain modification sustains neuronal viability in models of Alzheimer's diseaseConcurrence of Danish dementia and cataract: insights from the interactions of dementia associated peptides with eye lens alpha-crystallinNon-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta speciesTGF-beta1 blockade of microglial chemotaxis toward Abeta aggregates involves SMAD signaling and down-regulation of CCL5Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathwaysA cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaquesΒ-amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neuronsAmyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathwaysUltrafast colorimetric determination of predominant protein structure evolution with gold nanoplasmonic particles.Preparation of pure populations of covalently stabilized amyloid β-protein oligomers of specific sizes.Techniques for Monitoring Protein Misfolding and Aggregation in Vitro and in Living CellsSimultaneous monitoring of peptide aggregate distributions, structure, and kinetics using amide hydrogen exchange: application to Abeta(1-40) fibrillogenesisRole of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathwayAggregation and fibril morphology of the Arctic mutation of Alzheimer's Aβ peptide by CD, TEM, STEM and in situ AFMNeuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.Cognitive effects of cell-derived and synthetically derived Aβ oligomers.Anchored FRET sensors detect local caspase activation prior to neuronal degenerationToxic fibrillar oligomers of amyloid-β have cross-β structure.Mapping cofilin-actin rods in stressed hippocampal slices and the role of cdc42 in amyloid-beta-induced rods.Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease.RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivityStructure and dynamics of the Abeta(21-30) peptide from the interplay of NMR experiments and molecular simulations.Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity.Differentiating Alzheimer disease-associated aggregates with small molecules.Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide.Recombinant amyloid beta-peptide production by coexpression with an affibody ligand.Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment.Opposite effects of low and high doses of Abeta42 on electrical network and neuronal excitability in the rat prefrontal cortex.
P2860
Q21135583-F9C015DA-7620-4DB8-93B8-062E54A186AEQ21202837-38F9FE31-EC75-4168-B55E-9BA361725383Q24606835-36C73132-1A2B-4A9F-BFD9-6BB475817B20Q24630045-586EB6B1-C516-4C5B-921F-A76C606A4906Q24806882-A149DE22-584A-473B-8BDA-CC914FC4C1E0Q26822002-7780BD59-DE75-43AD-B702-D4663C10AEBCQ26830057-1E844AD7-201F-4C33-884B-7645FFC99564Q27013909-7409E791-473C-4633-9B39-E9CED5B9FD77Q27324934-0ABFBFFB-84C0-4F7D-BDF8-F4000B9662E7Q28085213-2DD7C161-4312-4ACA-AA9B-08A545D9ECC8Q28238942-C3E52B52-8954-4F70-A159-CF9317E5B8DFQ28239322-3B758B99-438E-467B-88DD-9DE5ECE719FDQ28278644-C41DE06B-5E72-466C-A960-1ABBCBF30913Q28473335-106DA501-E914-4DB6-A3AA-A370C8361AE3Q28478000-509AE2DE-733B-4442-9C34-9A1D7BE6729BQ28568787-1C60ED11-E9C0-4AE2-9FF8-E4DE8149BA6EQ28575781-33EB0591-EEB8-4851-809B-B2B7DD540BE9Q28740910-2E4FD649-B06E-4FDE-A337-74E1334C3DA8Q28744126-11C9FB6C-4A0C-4730-BD3E-DAC590FC7565Q30175699-C3845A0D-0CA2-4EFB-823C-48282309BB8DQ30380655-0E6A81D0-672B-4CED-A8AA-8DE302D8F361Q30394852-C79B021C-4B58-4EC5-982C-8AB1ED25CA30Q30420104-345DD6D9-9FCC-4317-8B70-9458B4C7DE37Q30438164-677F4C5A-03C9-4612-8220-51A375DDE492Q30443312-994CAA3A-0DEB-4F4B-84FA-46459D127184Q30448740-B5732492-C043-4600-8A23-52FCA9062F0EQ30489052-FF680A6F-AE3C-4019-8B00-17D950BAAE0EQ30495253-0330BC31-040B-4ED6-A1FA-1B8DF877EA1DQ30501542-E4091047-ED76-46A6-BEAC-0B6319B3C39BQ30514124-B6472B9B-C286-49A3-B271-DFBEAE95A996Q30655361-47772C04-0F92-447A-ABA2-6D551114B648Q30835636-02BCB769-5A0C-43E1-BD05-45ED0C58E2F6Q30879431-7F1872FF-E93A-4B12-840A-62445F1F8E8AQ31152625-36B8D863-6BB9-4E93-84A0-356790A3AC74Q33266053-1E4E6B60-E43C-41C9-813D-261119979031Q33296123-9DFEF895-8EC1-4675-9795-F3611A9E8D2DQ33320694-9E78FA9F-1C0B-4B1E-9EE5-D84E75AD4BCCQ33381404-644FF057-1F5B-4EBD-9F8C-135237C22F4EQ33382120-DEF1E762-B172-41C6-921A-5DB8B9E806BFQ33520211-5ED83902-4BC4-4E00-991F-B5EAC4A8F668
P2860
In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vitro characterization of c ...... erization and fibrillogenesis.
@ast
In vitro characterization of c ...... erization and fibrillogenesis.
@en
In vitro characterization of c ...... erization and fibrillogenesis.
@nl
type
label
In vitro characterization of c ...... erization and fibrillogenesis.
@ast
In vitro characterization of c ...... erization and fibrillogenesis.
@en
In vitro characterization of c ...... erization and fibrillogenesis.
@nl
prefLabel
In vitro characterization of c ...... erization and fibrillogenesis.
@ast
In vitro characterization of c ...... erization and fibrillogenesis.
@en
In vitro characterization of c ...... erization and fibrillogenesis.
@nl
P2093
P356
P1476
In vitro characterization of c ...... erization and fibrillogenesis.
@en
P2093
Grant A Krafft
Karie N Dahlgren
Mary Jo LaDu
W Blaine Stine
P304
11612-11622
P356
10.1074/JBC.M210207200
P407
P577
2002-12-23T00:00:00Z